TITAN PHARMACEUTICALS Trademark

Trademark Overview

On Friday, May 19, 2017, a trademark application was filed for TITAN PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the TITAN PHARMACEUTICALS trademark a serial number of 87457505. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 9, 2024. This trademark is owned by Titan Pharmaceuticals, Inc.. The TITAN PHARMACEUTICALS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency dise...
titan pharmaceuticals

General Information

Serial Number87457505
Word MarkTITAN PHARMACEUTICALS
Filing DateFriday, May 19, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 9, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 14, 2022

Trademark Statements

Goods and ServicesPharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases
NOT AVAILABLE"PHARMACEUTICALS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 25, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTitan Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameTitan Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events

Event DateEvent Description
Monday, August 21, 2017NON-FINAL ACTION WRITTEN
Tuesday, May 23, 2017NEW APPLICATION ENTERED
Thursday, May 25, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 18, 2017ASSIGNED TO EXAMINER
Monday, August 21, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 21, 2017NON-FINAL ACTION E-MAILED
Wednesday, November 1, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, November 1, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 1, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 6, 2017SUSPENSION LETTER WRITTEN
Monday, November 6, 2017LETTER OF SUSPENSION E-MAILED
Monday, November 6, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, May 30, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, March 28, 2018ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Thursday, May 24, 2018ASSIGNED TO LIE
Thursday, May 24, 2018REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, November 29, 2018REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, December 9, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Saturday, June 20, 2020REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, January 29, 2021SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Saturday, February 6, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, September 13, 2021SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Friday, September 17, 2021REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, May 11, 2022SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Thursday, May 12, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 25, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 14, 2022PUBLISHED FOR OPPOSITION
Thursday, January 19, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, June 14, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 9, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 19, 2023SOU EXTENSION 1 FILED
Thursday, January 19, 2023SOU EXTENSION 1 GRANTED
Saturday, January 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 17, 2023SOU EXTENSION 2 FILED
Monday, July 17, 2023SOU EXTENSION 2 GRANTED
Wednesday, July 19, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 17, 2023SOU TEAS EXTENSION RECEIVED
Monday, September 9, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, September 9, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Wednesday, December 27, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, December 27, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, December 27, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sunday, January 28, 2024SOU TEAS EXTENSION RECEIVED
Sunday, January 28, 2024SOU EXTENSION 3 FILED
Sunday, January 28, 2024SOU EXTENSION 3 GRANTED
Tuesday, January 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

pharmaceuticals titan disorders disease systems cardiovascular circulatory blood bronchial intestinal autoimmune enzyme